Donor screening gets treated as a box that either is or is not ticked, which is roughly as useful as describing a car as having an engine. Screening answers a narrow and important question about safety. It does not answer the question most research programs actually care about, which is how a given donor’s cells will behave. Those are two different programs, and conflating them is why buyers end up surprised by variance they had no way to predict.
What screening is protecting, and who
Infectious disease screening on donor material protects two groups, and the second is usually forgotten. The obvious one is any eventual downstream recipient. The less obvious one is everybody who handles the material in between, which for research products means your laboratory staff.
Primary human cells are handled by people at a bench, often for months. Screening is what makes that routine rather than hazardous, which is why it is applied to research material at all, given that most of it will never approach a patient.
What a multi-marker panel covers
A screening panel tests donor material against a defined set of transmissible agents. OrganaBio documents a 14-marker infectious disease screening panel across its donor program, applied to material including leukopaks, cryopreserved PBMCs and the isolated populations derived from the same donors.
What matters for interpretation is that a panel is defined rather than exhaustive. It tests for what it tests for. A result is a statement about those markers, and reading it as a general statement about biological safety is an overreach that the certificate itself does not make.
Before collection, or after
This distinction changes what a supplier can offer, and it is invisible on a certificate because both routes produce one.
Screening applied at donor program level means the pool is characterized before you order. Donors are known, and material can be selected against donor attributes because those attributes are already on record. Screening applied to material after collection means the result is attached to a lot that already exists, and your criteria were never selection criteria; they were a filter over inventory.
The consequence shows up when you need something specific. A program-level supplier can schedule a collection against your criteria, subject to availability. An inventory-level supplier can tell you whether something matching happens to be in a freezer.
Screening and characterization are different programs
| Safety screening | Donor characterization | |
|---|---|---|
| Question it answers | Is this material safe to handle and use | How is this material likely to behave |
| Typical content | Defined infectious disease marker panel | HLA genotype, KIR genotype, donor attributes |
| Result is | Pass or fail, binary | Descriptive, and useful as an experimental variable |
| If it is missing | The material should not be handled | Variance in your data becomes unexplainable |
| Can it be applied retrospectively | Yes, to existing material | Yes, but too late to have selected on it |
Buyers conflate these constantly, usually because both arrive on the same page. Screening tells you the material will not hurt anyone. Characterization tells you why donor four behaved differently from donors one through three.
What characterization adds
OrganaBio documents high-resolution NGS HLA genotyping across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP, together with KIR genotyping, as part of the donor program rather than as a per-order add-on. Donor attributes including age, sex, ethnicity, blood type, cytomegalovirus and Epstein-Barr virus status, BMI, smoking status and disease state can be used as selection criteria, subject to availability.
The reason this matters is that several of those attributes are known to move functional results. HLA type determines which peptides a donor can present, which makes it a hard constraint on any T cell assay. KIR genotype, read against target HLA class I, shapes NK behavior, covered in more depth in the NK cell guide. Prior cytomegalovirus exposure reshapes the memory compartment substantially. None of that appears in a viability figure.
Consent and provenance
Ethically sourced material carries documented, informed consent covering research use, obtained under an approved protocol. This is not a formality that can be reconstructed later. Provenance either exists in the record from the point of collection or it does not exist at all, and material without it is unusable for any program that may one day need to demonstrate where its inputs came from.
The question worth asking is who obtained the consent. A supplier collecting through its own operation can answer directly. A supplier reselling material collected elsewhere is relaying an answer, which is a weaker position on the one attribute that cannot be retrofitted.
What to ask
Ask whether screening is applied at donor program level or per lot. Ask which attributes are available as selection criteria rather than merely as documentation. Ask whether HLA and KIR genotype are known before you order. Ask who obtained consent and under what protocol. And ask what happens if you need the same donor again, because a screened and characterized donor you cannot return to is a resource with an expiry date attached.
Frequently asked questions
What does donor screening test for in research cell products?
A defined panel of transmissible agents. OrganaBio documents a 14-marker infectious disease screening panel across its donor program. A panel is defined rather than exhaustive, so a result is a statement about those specific markers rather than a general statement about biological safety.
Why is donor screening needed for research-only material?
Because primary human cells are handled by laboratory staff at a bench, often over months. Screening protects the people handling the material as much as any eventual downstream recipient, which is why it applies to research products that will never approach a patient.
What is the difference between donor screening and donor characterization?
Screening answers whether material is safe to handle and returns a binary result. Characterization, covering HLA genotype, KIR genotype and donor attributes, describes how material is likely to behave and functions as an experimental variable. Screening prevents harm; characterization explains variance.
Does it matter whether screening happens before or after collection?
Yes, though both produce a certificate. Program-level screening means the donor pool is characterized before you order, so material can be selected against donor attributes. Screening applied to existing lots means your criteria act as a filter over inventory rather than as selection criteria.
Which donor attributes can affect my results?
HLA type constrains which peptides a donor can present, which affects any T cell assay. KIR genotype read against target HLA class I shapes NK behavior. Prior cytomegalovirus exposure substantially reshapes the memory compartment. None of these are visible in a viability figure.
Why can consent and provenance not be added later?
Because documented informed consent obtained under an approved protocol either exists in the record from the point of collection or it does not exist at all. Material lacking it is unusable for any program that may later need to demonstrate the origin of its inputs.
What should I ask a supplier about donor screening?
Whether screening is applied at program level or per lot, which attributes are available as selection criteria rather than only as documentation, whether HLA and KIR genotype are known before ordering, who obtained consent and under what protocol, and whether the same donor can be collected from again.
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
